RenovoRx, Inc. (RNXT) income statement
RNXTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$1.04+0.09 (+8.91%)
Close on Nov 17, 2026Market cap $46.93MP/E –Yield –
RenovoRx, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 84.4%
- Operating margin
- -685.2%
- Net margin
- -621.7%
- Return on equity, FY2025
- -225.6%
Financial strength
- Current ratio
- 5.74
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 503.1%
Valuation
- P/E ratio
- –
- Price to sales
- 23.75
- Price to book
- 5.23
- Dividend yield
- –
See a number that looks wrong?